Gene Therapy Casgevy denied as experimental or investigational by Humana?

Humana's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Casgevy as Experimental or Investigational

Casgevy (exagamglogene autotemcel) received FDA approval for sickle cell disease and transfusion-dependent beta-thalassemia. An "experimental or investigational" denial for an FDA-approved therapy is therefore based on Humana's internal clinical policy standard — which can set a higher evidentiary bar than FDA approval alone — or it may reflect a coding, documentation, or policy-update lag that can be corrected on appeal.

This denial is one of the most compelling to contest: FDA approval is the foundational regulatory determination that a therapy is safe and effective for its labeled indication. An insurer's E&I policy that overrides FDA approval as a matter of categorical exclusion faces significant legal and clinical scrutiny on external review.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Request the specific language from Humana's clinical policy that classifies Casgevy as experimental, and which criteria it fails. Submit your appeal within the deadline on your denial notice.
• External review: After the internal appeal, IRO review is available within approximately four months of the final internal denial. For a gene therapy with FDA approval, IRO reviewers will assess whether Humana's E&I classification is consistent with generally accepted standards of care.
• Expedited review: Highly appropriate here — sickle cell disease and beta-thalassemia can carry urgent, life-threatening complications. Request expedited processing in writing.
• State insurance department complaint: If Humana's policy categorically excludes an FDA-approved therapy for its approved indication, a concurrent complaint to your state's insurance commissioner may apply additional pressure.

## Building a Strong Appeal

### Documentation to Gather

1. FDA approval documentation: Confirm the FDA approval date and approved indication(s) for Casgevy. Include the FDA label or a reference to the approval letter. State explicitly that the requested use matches the approved indication. 2. Humana's E&I policy: Obtain the current version of Humana's clinical policy for gene therapies or specifically for Casgevy. Identify each criterion the policy uses to define "experimental" and confirm whether any of those criteria are actually unmet for an FDA-approved therapy. 3. Professional society recognition: Obtain a reference to the applicable professional society guideline (e.g., American Society of Hematology) acknowledging Casgevy as a recognized treatment option for the relevant diagnosis. 4. Disease severity and eligibility documentation: Current and longitudinal records of disease burden, including transfusion history, hospitalization history, vaso-occlusive event frequency, and organ involvement. Your specialist should document that you meet the clinical criteria in the FDA-approved label — without quoting numeric thresholds; instead, reference that the chart contains the relevant measurements and that the prescribing physician has confirmed eligibility per the label. 5. Prescriber medical-necessity and eligibility letter: Your treating hematologist or specialist should attest that: (a) you carry the confirmed diagnosis, (b) your clinical profile meets the eligibility criteria described in the FDA-approved prescribing label, (c) Casgevy is not being used off-label, and (d) the treatment is consistent with the applicable professional society's guidance. 6. Prior treatment history: Documents the treatments tried before Casgevy, their outcomes, and the clinical rationale for proceeding to gene therapy.

### Criteria-Mapping Structure

List each element of Humana's E&I definition. For each element: - If it requires FDA approval: cite the FDA approval date and approved indication. - If it requires professional society recognition: cite the relevant guideline organization. - If it requires evidence of clinical effectiveness: reference the existence of published peer-reviewed evidence without quoting statistics. - If any element remains genuinely unmet, address it directly rather than leaving it blank.

## Key Message to Your Treating Specialist

The strongest argument here is simple: Casgevy carries FDA approval for the exact indication being requested, and that approval reflects a rigorous regulatory finding of safety and efficacy. The appeal letter should lead with that fact, then systematically address each element of Humana's E&I policy. If the policy predates the FDA approval date, explicitly note that the policy has not been updated to reflect current regulatory status — this is a common and correctable basis for reversal.